Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients
DOI:
https://doi.org/10.51699/ijhsms.v1i1.35Keywords:
COVID-19, SARS-CoV-2, coronavirus infection, hydroxychloroquine, favipiravirAbstract
The article presents the results of a post-registration observational study to evaluate the results of early initiation of antiviral therapy in patients with COVID-19 receiving treatment at home.
Goal- to evaluate the efficacy and safety of antiviral therapy for the treatment of outpatient patients with coronavirus infection caused by SARS-COV-2.
Materials and methods. The study included 200 outpatient patients with COVID-19. According to etiotropic therapy, patients were divided into 3 groups: those who received favipiravir, hydroxychloroquine and those who did not receive antiviral agents.
Results. The average time to virus elimination while taking favipiravir was 3 (3.0-5.0) days, among those receiving hydroxychloroquine – 5 (4.0-6.0) days, without antiviral therapy – 8.5 (7.0-10.0) days. Normalization of body temperature occurred faster with favipiravir therapy.
Conclusions. Antiviral therapy in outpatient patients with COVID-19 is effective and safe. . Taking favipiravir promotes earlier elimination of the virus, faster normalization of body temperature and a favorable outcome of the disease. Hydroxychloroquine may be prescribed as an alternative antiviral drug to outpatient patients in the absence of a risk of severe course..
